Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines

Epigenetics

Volumn 6, Issue 12, 2011, Pages 1413-1424

  Prando, Érika da Costa ^a   Cavalli, Luciane Regina ^b   Rainho, Cláudia Aparecida ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer cell lines; DNA methylation; Gene expression; Histone modification; RASSF1; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CALCIUM CHANNEL; CALCIUM CHANNEL VOLTAGE DEPENDENT ALPHA2 DELTA2; HYALURONIDASE; HYALURONIDASE TYPE 1; HYALURONIDASE TYPE 2; HYALURONIDASE TYPE 3; MEMBRANE PROTEIN; NITROGEN PERMEASE REGULATOR LIKE PROTEIN 2; PERMEASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SEMAPHORIN; SEMAPHORIN 3B; TRANSMEMBRANE PROTEIN 115; TRICHOSTATIN A; TUMOR SUPPRESSOR CANDIDATE 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; EPIGENETICS; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL;

EID: 83255166586     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.12.18271     Document Type: Article

References (45)

1. Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL. An integrative multi-dimensional genetic and epigenetic strataegy to identify aberrant genes and pathways in cancer. BMC Biosystems Biology 2010; 4:67-80; DOI:10.1186/1752-0509-4-67.
2. Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, et al. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 2010; 29:73-93; DOI:10.1007/s10555-010-9199-2.
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; DOI:10.1016/j. cell.2007.01.029.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59; PMID:18337604; DOI:10.1056/ NEJMra072067.
5. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; DOI:10.1093/carcin/bgp220.
6. Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS, et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res 2006; 66:10664-70; DOI:10.1158/0008-5472.CAN-06-2761.
7. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res 2008; 68:8616-25; DOI:10.1158/0008-5472.CAN-08-1419.
8. Clark SJ. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum Mol Genet 2007; 16:88-95; DOI:10.1093/hmg/ddm051.
9. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38:540-9; DOI:10.1038/ng1781.
10. Hitchins MP, Lin VA, Buckle A, Cheong K, Halani N, Ku S, et al. Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Res 2007; 67:9107-16; DOI:10.1158/0008-5472.CAN-07-0869.
11. Karpinski P, Ramsey D, Grzebleniak Z, Sasiadek MM, Blin N. The CpG isaland methylator phenotype correlates with long range epigenetic silencing in colorectal cancer. Mol Cancer Res 2008; 6:585-91; DOI:10.1158/1541-7786.MCR-07-2158.
12. Mayor R, Casadomé L, Azuara D, Moreno V, Clark SJ, Capellà G, et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer 2009; 100:1534-9; DOI:10.1038/sj.bjc.6605045.
13. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, et al. Regional copy numberindependent deregulation of transcription in cancer. Nat Genet 2006; 38:1386-96; DOI:10.1038/ng1923.
14. Devaney J, Stirzaker C, Qu W, Song JZ, Statham AL, Patterson KI, et al. Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol Biomarkers Prev 2011; 20:148-59; DOI:10.1158/1055-9965.EPI-10-0719.
15. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 2010; 12:235-46.
16. Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet 2009; 5:1000745; DOI:10.1371/ournal.pgen.1000745.
17. Martinez A, Walker RA, Shaw JA, Dearing SJ, Maher ER, Latif F. Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 2001; 54:300-6; DOI:10.1136/mp.54.5.300.
18. Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 2001; 159:119-30; DOI:10.1016/ S0002-9440(10)61679-3.
19. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007; 1776:58-85. DOI; 10.1016/ j.bbcan.2007.06.003.
20. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer: from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114-28. DOI:10.1016/ j.bbcan.2009.03.004.
21. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 2007; 26:7283-301; DOI:10.1038/ sj.onc.1210547.
22. Ji L, Minna JD, Roth JA. 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol 2005; 1:79-92; DOI:10.1517/14796694.1.1.79.
23. Sekido Y, Ahmadian M, Wistuba I, Latif F, Bader S, Wei MH, et al. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998; 16:3151-7; DOI:10.1038/sj.onc.1201858.
24. Lerman MI, Minna JD. The 630 Kb lung cancer homozygous deletion region on chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res 2000; 60:6116-33.
25. Hsu PY, Hsu HK, Singer GAC, Yan PS, Rodriguez BAT, Liu JC, et al. Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. Genome Res 2010; 20:733-44; DOI:10.1101/gr.101923.109.
26. Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004; 23:2408-19; DOI:10.1038/sj.onc.1207407.
27. Ito M, Ito G, Kondo M, Uchiyama M, Fukui T, Mori S, et al. Frequent inactivation of RASSF1A, BLU and SEMA3B on3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 2005; 225:131-9; DOI:10.1016/j.canlet.2004.10.041.
28. Senchenko VN, Anedchenko EA, Kondratieva TT, Krasnov GS, Dmitriev AA, Zabarovska VI, et al. Simultaneous downregulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer 2010; 1:10:75. DOI:10.1186/1471-2407-10-75.
29. Lai HC, Lin YW, Chang CC, Wang HC, Chu TW, Yu MH, et al. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol 2007; 104:629-35; DOI:10.1016/j. ygyno.2006.10.003.
30. Lai HC, Lin YW, Chang CC, Wang HC, Chu TW, Yu MH, et al. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol 2007; 104:629-35; DOI:10.1016/j. ygyno.2006.10.003.
31. Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 2009; 19:165-71; DOI:10.1016/j. semcancer.2009.02.007.
32. Reeves ME, Baldwin SW, Baldwin ML, Chen ST, Moretz JM, Aragon RJ, et al. Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis. BMC Cancer 2010; 10:562; DOI:10.1186/1471-2407-10-562.
33. Estrabaud E, Lassot I, Blot G, Le Rouzic E, Tanchou V, Quemeneur E, et al. RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of beta-catenin by interacting with betaTrCP. Cancer Res 2007; 67:1054-61; DOI:10.1158/0008-5472.CAN-06-2530.
34. Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The overexpression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005; 310:205-17; DOI:10.1016/j. yexcr.2005.07.026.
35. Bertrand P, Girard N, Duval C, d'Anjou J, Chauzy C, Menard JF, et al. Increased hyaluronidase levels in breast tumor metastases. Int J Cancer 1997; 73:327-31; DOI:10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1.
36. Tan JX, Wang XY, Li HY, Su XL, Wang L, Ran L, et al. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Int J Cancer 2011; 128:1303-15; DOI:10.1002/ ijc.25460.
37. Lokeshwar VB, Gomez P, Kramer M, Knapp J, McCornack MA, Lopez LE, et al. Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem 2008; 283:29215-27; DOI:10.1074/jbc.M801101200.
38. Lokeshwar VB, Selzer MG. Hyalurondiase: both a tumor promoter and suppressor. Semin Cancer Biol 2008; 18:281-7; DOI:10.1016/j. semcancer.2008.03.008.
39. Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer 2004; 109:839-47; DOI:10.1002/ ijc.20079.
40. Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within critical 3p21.3 region in gliomas. Oncogene 2004; 23:2408-19; DOI:10.1038/sj.onc.1207407.
41. Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA, et al. CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene 2003; 22:615-26; DOI:10.1038/sj.onc.1206134.
42. Komashko VM, Farnham PJ. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010; 5:229-40; DOI:10.4161/epi.5.3.11409.
43. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 2002; 62:6456-61.
44. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 2009; 50:455-63; DOI:10.3349/ymj.2009.50.4.455.
45. Mayor R, Munõz M, Coolen MW, Custodio J, Esteller M, Clark SJ, et al. Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells. Epigenetics 2011; 6:1138-48.